argenx SE ADR Stock News

Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.

LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.

Shares in argenx SE (NASDAQ:ARGX) fell nearly 15% in New York on Thursday after it discontinued a late-stage trial of its drug Vyvgart in Sjögren's disease. Sjögren's disease is a chronic autoimmune condition characterized by immune-mediated destruction of the glands that produce tears and saliva, causing symptoms including dry eyes and mouth.

Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response.

Argenx said on Thursday it had discontinued a late-stage study of its efgartigimod ​drug in adults with Sjögren's disease, ‌an autoimmune condition that damages the glands producing tears and saliva, putting its shares on track ​for their biggest one-day fall in ​almost three years.

The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET    Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation co...